CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 49,125 shares at an average $43.27 ($2,125,795)
- 4 Open-market sale 10% owner sold 370,000 shares at $40.18 ($14,866,600)
- 4 Exercise or conversion Chief Medical Officer acquired 5,515 shares (option exercise)
- 4 Open-market buy IA/Managing Member of 10% Owne bought 8,690 shares at an average $57.33 ($498,172)
- 4 Open-market buy Director bought 44,648 shares at an average $55.35 ($2,471,251)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion Chief Medical Officer acquired 5,515 shares (option exercise)
- 4 Open-market buy Director bought 30,000 shares at $17.00 ($510,000)
- 4 Open-market buy Director bought 2,875 shares at $17.00 ($48,875)
- 4 Open-market buy Director bought 550 shares at $17.00 ($9,350)
- 4 Grant or award Director acquired 30,000 shares (grant or award)
- 4 Exercise or conversion Chief Medical Officer acquired 17,231 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 9 of 11 · 211 filings